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ARTICLE
Perturbed structural dynamics underlie inhibition
and altered efflux of the multidrug resistance
pump AcrB
Eamonn Reading 1,5,6✉, Zainab Ahdash1,5, Chiara Fais2, Vito Ricci3, Xuan Wang-Kan 3, Elizabeth Grimsey3,
Jack Stone3, Giuliano Malloci 2, Andy M. Lau1, Heather Findlay1, Albert Konijnenberg4, Paula J. Booth1,
Paolo Ruggerone 2, Attilio V. Vargiu 2, Laura J. V. Piddock 3 & Argyris Politis 1,6✉
Resistance–nodulation–division efflux pumps play a key role in inherent and evolved multi-
drug resistance in bacteria. AcrB, a prototypical member of this protein family, extrudes a
wide range of antimicrobial agents out of bacteria. Although high-resolution structures exist
for AcrB, its conformational fluctuations and their putative role in function are largely
unknown. Here, we determine these structural dynamics in the presence of substrates using
hydrogen/deuterium exchange mass spectrometry, complemented by molecular dynamics
simulations, and bacterial susceptibility studies. We show that an efflux pump inhibitor
potentiates antibiotic activity by restraining drug-binding pocket dynamics, rather than pre-
venting antibiotic binding. We also reveal that a drug-binding pocket substitution discovered
within a multidrug resistant clinical isolate modifies the plasticity of the transport pathway,
which could explain its altered substrate efflux. Our results provide insight into the molecular
mechanism of drug export and inhibition of a major multidrug efflux pump and the directive
role of its dynamics.
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AcrB is a homotrimeric integral membrane protein thatforms part of the tripartite AcrAB-TolC efflux pump1(Fig. 1a, b and Supplementary Fig. 1). Energized by the
proton-motive force, AcrB transports a broad variety of toxic
substances, including antibiotics, outside of the cell through a
channel formed by the periplasmic adaptor protein, AcrA, and
outer membrane channel, TolC2,3. It is constitutively expressed
in many pathogenic Gram-negative bacteria and, with its
homologues forming the most clinically relevant pumps, has
become a target for drug discovery to tackle multidrug resistance
(MDR)4–7.
Previous structural and biochemical work has enabled
drug-binding pockets and efflux pathways for AcrB to be pro-
posed1,2,7–17. Drug transport is purported to occur via coopera-
tive rotation between three distinct monomer conformations:
loose (L), tight (T), and open (O) (Fig. 1c). Where, in the L-state,
drugs gain access to the proximal binding pocket (PBP) through
entrance channels1,8,18. Upon a conformational change to the T-
state, the drug is then moved towards the distal binding pocket
(DBP) before being transported through the exit channel of the
periplasmic domain, following a second conformational change
from the T- to O-state19,20. A switch-loop (615FGFAGR620) acts
to separate the PBP from the DBP (Fig. 1b); the conformational
flexibility of this region is proposed to be essential for the reg-
ulation of substrate binding and export21,22.
Each AcrB monomer contains a connecting-loop, which pro-
trudes into the Funnel Domain (DC and DN subdomains) of the
adjacent monomer (Fig. 1a) and has been shown to be important
for stabilizing the trimer during the functional rotation23. During
rotation, the transmembrane (TM) region—which consists of the
R1 (TM1-6) and R2 (TM7-12) domains connected by the Iα-helix
(520FEKSTHHYTDSVGGIL535) (Fig. 1a, b)—is also postulated to
move considerably14,24.
Despite the availability of high-resolution structures of AcrB, it
has remained challenging to dissect how its molecular mechan-
isms are regulated by naturally occurring MDR mutations, efflux
pump inhibition and their synergy with antibiotics. One funda-
mental aspect of its structure that remains unresolved concerns
the role of its structural dynamics, which are often crucial for
protein function25–28. Here, we use hydrogen/deuterium exchange
mass spectrometry (HDX-MS) to directly measure changes in
AcrB structural dynamics owing to binding of the ciprofloxacin
(CIP) antibiotic and the well-studied phenylalanine-arginine-β-
naphthylamide (PAβN) efflux pump inhibitor (EPI)5,7,15,29.
Investigating both wildtype AcrB (AcrBWT) and a recently dis-
covered G288D mutation (AcrBG288D), uncovered in a post-
therapy MDR clinical isolate of Salmonella Typhimurium30, we
were able to further understand the structural and functional
consequences of substrate and inhibitor binding and clinically
relevant mutation.
In this work, we reveal that the PAβN EPI restricts the
intrinsic motions of the drug-binding pockets as part of its
mechanism of action and is effective against both AcrBWT and
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Fig. 1 Summary of structure, function, and HDX-MS of AcrB. a Structure and subdomains of AcrB (PDB:2HRT). b Highlighted regions of functional
interest on AcrB monomeric unit. c Functional rotation drug efflux mechanism between the three distinct monomer conformations within trimeric AcrB.
d HDX-MS workflow.
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to AcrB alongside an antibiotic, without affecting its inhibi-
tory action. We discover that an MDR mutation in acrB
impacts upon the structural dynamics of the efflux translo-
cation pathway, likely contributing to its modified substrate
efflux. Structural dynamics therefore have a critical role in the
inhibition and substrate efflux of AcrB. Understanding the
effect of these dynamics on structure and function is critical
for successful assessment of resistance–nodulation–division
(RND) efflux pump mechanism and inhibition, especially in
relation to MDR-conferring mutations.
Results
HDX-MS of AcrB. HDX-MS is a solution-based method which
can provide molecular-level information on local protein struc-
ture, stability, and dynamics31–33. HDX occurs when backbone
amide hydrogens are made accessible to D2O solvent through
structure unfolding and H-bond breakage; HDX is fast within
unfolded regions and slow within stably folded regions (i.e. α-
helices, β-sheet interiors), where local structural fluctuations
which expose an otherwise protected amide hydrogen to
solvent transiently are required for HDX to occur. In order to
decipher the effect of drug binding and mutation on AcrB
structural dynamics, we performed differential HDX
(ΔHDX) analysis between two conditions (e.g. drug-bound and
drug-free), which is a sensitive approach for detecting associated
structural perturbations between two different protein states
(Fig. 1d)33–35.
We optimized HDX-MS conditions on Escherichia coli (E. coli)
AcrB solubilized within n-Dodecyl-β-D-Maltopyranoside (DDM)
detergent micelles achieving 72% peptide coverage (Supplemen-
tary Fig. 2). A relative fractional deuterium uptake analysis of
AcrB revealed that many of its residues form part of stable
structures, inferred from the longest labelling time points (0.5–1
h) required for substantial deuterium incorporation32 (Supple-
mentary Figs. 3, 4). Its most structurally dynamic regions being
discovered within the subdomains of the Porter Domain (PC1,
PC2, PN1, and PN2) which, notably, host the main drug-binding
pockets (Fig. 1a, b and Supplementary Table 1). Lack of extensive
HDX was observed within the TM domains, likely afforded by
their protection within the hydrophobic environment of the
detergent micelle.
EPI restricts drug-binding pocket dynamics. First, we examined
how CIP and PAβN binding affects AcrBWT structural dynamics.
CIP is a licensed antibiotic in clinical use and has been demon-
strated to bind to the DBP, PC1/PC2 cleft and central cavity by
MD simulations and X-ray crystallography15,29. While PAβN, an
EPI and substrate of AcrB, has been shown to bind to similar
areas of AcrB as many antibiotics, this binding may be at distinct
sites5,15,29.
In the presence of CIP only a few regions within the
PN2 subdomain, central cavity, R2 domain (TM 7-12) and Iα-
helix demonstrated significant differential HDX (Fig. 2a, b),
suggesting that CIP binding only subtly alters the structural
motions of AcrBWT. The presence of PAβN gave comparably
increased HDX within the PN2 subdomain. However, in stark
contrast to CIP, inhibitor binding led to HDX reduction
throughout extensive parts of the PC1/PC2 cleft of the drug-
binding pockets and within the connecting-loop (Fig. 2a, b and
Supplementary Fig. 5). This could signify inhibitor-induced
structural stabilization of the drug-binding pocket entrances.
HDX of the Iα-helix did not significantly change upon addition
of PAβN, whereas HDX was substantially increased upon CIP
binding (Fig. 2a), possibly because the inhibitor weakens the
coupling between the R1 and R2 TM domains. Notably, switch-
loop spanning peptides with reduced HDX were detected when
PAβN was present, which may reflect a binding interaction and/
or structural stabilization (Fig. 2a, b and Supplementary Fig. 5).
Together, our HDX data support an inhibitory mode of action
by which an EPI primarily acts to impart concerted restraint on
AcrB structural dynamics, notably restricting the drug-binding
pockets, connecting- and switch-loops.
Multi-copy 1-μs long MD simulations of AcrBWT bound to
PAβN confirmed that—in agreement with the previous literature6
—the inhibitor could stably bind to the DBP, straddling the
switch-loop and establishing strong interactions with the
hydrophobic trap (HT); a peculiar region of the DBP rich in
phenylalanines and involved in EPI binding4,36 (Supplementary
Fig. 6).
To further understand the dynamics of AcrB in the presence of
substrates, Root Mean Square Fluctuation (RMSF) and first
hydration shell profiles were compared to the HDX-MS data. The
average number of water molecules in the first amide NH
solvation shell computed by MD simulations has been found to
correlate well with HDX37. A reduced hydration shell should
therefore imply reduced HDX, due to the decrease in specific
interactions between amide N–H bonds and the solvent.
However, protein HDX is complex, with neighbouring residues
having significant differences in their solvent interactions, this
combined with the stark contrast between MD simulation and
HDX-MS experimental time scales (µs to ms versus seconds to
hours) means that a simple quantitative comparison can often be
incomplete. Nevertheless, comparisons to MD calculated hydra-
tion profiles can provide informative qualitative interpretation of
protein HDX.
MD analysis of AcrBWT-PAβN (T monomer) and apo AcrBWT
(L monomer) revealed that binding of PAβN is accompanied by
an overall rigidification of the protein (Supplementary Fig. 7; see
also Supplementary Discussion and Supplementary Tables 2, 3),
which involves large patches of the DBP, PBP, switch-loop, as
well as the exit channel gate (EG), CH1, and CH2 channels8. In
particular: (i) regions containing residues belonging/adjacent to
the switch-loop that were found to directly interact with PAβN
become more rigid in its presence, the extent of HDX protection
upon PAβN binding (as revealed by the HDX-MS data)
correlating with the formation of hydrogen bonds between the
EPI and residues of (and nearby) the DBP; ii) the switch-loop
itself (residues 615–620) features moderately enhanced hydration,
whereas the nearby segments (residues 612–614 and 621–624) are
overall dehydrated with respect to apo AcrBWT. This supports an
interaction between PAβN and the switch-loop region, which we
anticipate being a key factor in mediating the mode of action of
this EPI. More generally, the structural stabilization that occurs
upon PAβN binding might prevent local, as well as distal,
functional movements that are key to substrate efflux along the
transport pathway.
Overall, these data agree with a model for inhibitor action,
which has been proposed to work by trapping AcrB in a
conformation, possibly a T-like state, which prevents adequate
functional rotation and substrate transport16.
EPI and antibiotic can dually bind to AcrB. To fully understand
EPI action, it is essential to consider its activity in the presence of
antibiotic substrates, especially considering the emerging impor-
tance of drug combination therapies for treating bacterial infec-
tion38. Antibiotic susceptibility assays against E. coli confirmed
the ability of the PAβN EPI to potentiate antibiotic activity
(Fig. 2c). PAβN increased antibiotic susceptibility for a range of
antimicrobial AcrB substrates (ciprofloxacin (CIP), tetracycline
(TET), and chloramphenicol (CHL)) in a substrate-dependent
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manner, with better effectiveness observed at lower PAβN con-
centrations for CIP than for TET and CHL.
To explore the effect of an antibiotic on efflux inhibition we
performed HDX-MS in the presence of both CIP and PAβN
(AcrBWT-CIP-PAβN). We anticipated that the presence of
equimolar CIP may interfere with PAβN binding, thereby
affecting its ability to prevent functionality of the transporter
through dynamic restrain. This was not the case. The presence of
CIP did not alter the action of the PAβN inhibitor, as revealed by
the strikingly similar differential HDX profiles for both AcrBWT-
PAβN and AcrBWT-CIP-PAβN (Fig. 2a, b and Supplementary
Fig. 5). Consequently, we investigated the possibility that PAβN
acts by outcompeting CIP binding to AcrB. To test this, we
exploited the innate fluorescence of CIP to perform fluores-
cence polarization binding and competition assays39. Interest-
ingly, we found that CIP binds with comparable affinity to both
AcrBWT (KD of 74.1 ± 2.6 µM from Su et al.39) and a preformed
AcrBWT–PAβN complex (KD of 67.3 ± 13.2 µM) (Fig. 3a), and
that titration of PAβN EPI could not effectively outcompete
CIP binding from a AcrBWT–CIP complex (Fig. 3b). These
data suggest that antibiotic and inhibitor may be able to
simultaneously bind at different (sub)sites within the volumi-
nous DBP.
To further support this hypothesis, we performed blind docking
calculations and MD simulations on AcrBWT–PAβN–CIP (Sup-
plementary Figs. 8, 9). Importantly, both drugs stably bind to the
DBP within the T-state monomer, with PAβN partly occupying
the HT and CIP lying in proximity of the PBP/DBP interface
(Fig. 3c). The simultaneous binding of CIP and PAβN has similar
effects on the flexibility and hydration of the DBP as the binding
of PAβN only (Fig. 2a, b and Supplementary Fig. 10; see
Supplementary Discussion). Several interactions contribute to
stabilize this configuration, including the formation of hydrogen
bonds between the substrates and several residues of the DBP
(Supplementary Table 4) and stable intermolecular hydrogen
bonds between the two ligands (Supplementary Fig. 9).
Overall, our data support the hypothesis that PAβN does not
compete or prevent antibiotic binding (competitive inhibition).
Instead, we propose that it inhibits AcrB function by enforcing a
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Fig. 2 Effect of EPI PAβN on AcrB structural dynamics and function. a Sum differential HDX (ΔHDX) plots for different drug conditions (ΔHDX=
(AcrBWT+drug(s))−AcrBWT) for all time points collected. Red signifies peptides with increased HDX between states and blue represents peptides with
decreased HDX. 98% confidence intervals are shown as grey dotted lines and grey data are peptides with insignificant ΔHDX. All measurements were
performed at least in triplicate. All supporting HDX-MS peptide data can be found in the Source Data file. b ΔHDX extent for (AcrBWT+CIP+ PAβN) –
AcrBWT is coloured onto the L-state monomer of AcrB (PDB:2HRT) using Deuteros34. Connecting-loop from the adjacent monomer is included. Uptake
plot data are the average and standard deviation from repeated measurements (n= 3). c MIC assays of Escherichia coli in the presence of inhibitor and
antibiotics. Values that demonstrate >2-fold reduction in MIC are in bold. Ciprofloxacin = CIP, Tetracycline = TET, Chloramphenicol = CHL, and
phenylalanine-arginine-β-naphthylamide = PAβN. MIC for PAβN alone is 256 μg/ml.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19397-2
4 NATURE COMMUNICATIONS |         (2020) 11:5565 | https://doi.org/10.1038/s41467-020-19397-2 | www.nature.com/naturecommunications
magnitude of the conformational changes within the substrate
translocation path. Its effectiveness being substrate dependent.
MDR-conferring G288D mutation affects drug-binding pocket
dynamics. We next turned our attention to the substitution
mutation, G288D (AcrBG288D), which was found to cause resis-
tance to some drugs (e.g. CIP) in Salmonella, but susceptibility to
others (e.g. minocycline (MIN))30. G288 is a highly conserved
residue in Enterobacteriaceae30, suggesting an important struc-
tural role, and is present aside the HT within the DBP (Fig. 4a).
We found that the G288D substitution does not alter the oligo-
meric state, average secondary structure content or thermal sta-
bility of AcrB, as judged by native mass spectrometry and circular
dichroism (Supplementary Fig. 2). Yet, our HDX analysis
revealed that the G288D mutation has a noticeable effect on the
structural dynamics of AcrB. We observed that, when no drugs
were present, the G288D mutation caused increased HDX for
several peptides spanning the PN2 region of the protein, but
decreased HDX within the PC1/PC2 regions and the connecting-
loop (Fig. 4b). Seemingly, this single-point mutation can cause a
long-range change to the structural dynamics of AcrB, possibly
reflecting global conformational changes in its substrate-free
state.
Upon substrate binding, PAβN caused reduced HDX within
the PC1/PC2 regions for AcrBG288D (Supplementary Fig. 11), as
was observed for AcrBWT (Fig. 2a), with AcrBG288D-PAβN
having increased HDX reduction within PC1 and R2 (TM 7-12)
domains in comparison to AcrBWT–PAβN (Fig. 4b). This
supports that the PAβN EPI affects the dynamics of the different
AcrB genotypes in a similar manner, with AcrBG288D–PAβN
possibly undergoing further restraint than AcrBWT–PAβN.
Whereas CIP caused increased HDX throughout extensive
regions of AcrBG288D (Supplementary Fig. 11), bringing the
PC1/PC2 and DC regions of AcrBG288D closer in parity with
AcrBWT for both CIP and CIP–PAβN conditions (Fig. 4b).
Markedly, in the apo form and for all three substrate
conditions tested (CIP, PAβN, and CIP–PAβN), the G288D
substitution consistently caused increased HDX within the PN2
region and decreased HDX of the connecting-loop (Fig. 4b).
Signifying that these effects are retained even upon substrate
binding and, due to their close structural proximity, may relate to
concerted changes to the dynamics of the substrate translocation
pathway (Fig. 4c).
PAβN EPI inhibits both wildtype and G288D AcrB. MD
simulations of AcrBG288D in the presence of PAβN were per-
formed to better understand how the G288D mutation affects EPI
interactions with the drug-binding pockets. PAβN was found to
bind to the HT of AcrBG288D, interacting with the mutated D288
residue through the formation of direct and water-mediated
hydrogen bonds (Supplementary Fig. 12 and Supplementary
Table 5). Interactions with the aromatic residues of the HT
involve hydrophobic stacking as well as cation-π attraction, not
observed in AcrBWT–PAβN, and possibly promoted by the direct
interaction of the inhibitor with residue D288 (Supplementary
Table 6; see Supplementary Discussion). This interaction is sup-
ported by the reduced HDX found within D288 containing
peptides of AcrBG288D–PAβN (Supplementary Fig. 11b). More-
over, in accordance with HDX-MS, the switch-loop and the
surrounding DBP region undergo further dehydration in
AcrBG288D-PAβN (Supplementary Fig. 13) and are involved in
high-occurrence interactions with PAβN, similar to those formed
within AcrBWT–PAβN (Supplementary Tables 3, 6). These data,
together with the direct interactions detected between the EPI and
regions of the switch-loop, support the hypothesis that stabili-
zation of the latter has a role for inhibitor mode of action of
PAβN both in AcrBWT and in AcrBG288D.
Similar conclusions emerged from the comparison between
AcrBG288D–CIP–PAβN and AcrBWT–CIP–PAβN. Indeed, MD
simulations of the former complex revealed that, even upon
G288D substitution, CIP and PAβN can stably occupy the DBP at
the same time (Fig. 5a). As in AcrBWT–CIP–PAβN, stabilizing
interactions include several substrate contacts with the AcrBG288D
protein, also involving D288 (Supplementary Figs. 14, 15 and
Supplementary Table 7), as well as intermolecular hydrogen
bonds between the two ligands (Supplementary Table 8).
Fluorescence polarization binding and competition assays
support that a ternary AcrBG288D–CIP–PAβN is also possible
(Fig. 5b, c): (i) CIP binds to a preformed AcrBG288D–PAβN
complex (KD of 22.7 ± 2.9 µM) with similar, albeit slightly higher,
affinity compared to CIP binding to AcrBWT–PAβN (KD of
67.3 ± 13.2 µM); (ii) titration of the PAβN inhibitor could not
effectively outcompete CIP binding from AcrBG288D–CIP, as was
found for AcrBWT–CIP (Fig. 3b). Taken together, the fluores-
cence polarization binding assays and MD simulation data
advocate that AcrBG288D is inhibited by PAβN in a similar
manner as AcrBWT.
These findings were supported by bacterial susceptibility assays
on E. coli containing overexpressed AcrBG288D. AcrBG288D was
previously discovered within Salmonella clinical isolates30 and
found to have increased and decreased susceptibility to MIN and
CIP antibiotics, respectively. We chose, therefore, to study these







































Fig. 3 Dual binding of ciprofloxacin antibiotic and PAβN inhibitor to the
DBP of AcrBWT. a Binding of CIP by AcrBWT in the presence of 150 μM of
PAβN as determined by a fluorescence polarization assay performed by Su
et al.39. CIP was maintained at 1.5 µM throughout and its emission
wavelength measured at 415 nm. Reported data are the average and
standard deviation from independent measurements (n= 3) and were
fitted to a hyperbola function (FP= (Bmax*[protein])/(KD+ [protein]),
R2= 0.98). b Binding competition assay between PAβN and CIP for
AcrBWT. PAβN was non‐fluorescent in the experimental conditions. Data
are the average and standard deviation from independent measurements
(n= 3). c Molecular docking and multi-copy μs-long MD simulations reveal
stable interactions of CIP (orange) and PAβN (cyan) to AcrBWT T-state
monomer and show their likely binding locations. EG= exit channel gate
(blue spheres), SL= switch-loop (yellow), and HT= hydrophobic trap
(purple). All computational data can be found in Supplementary Table 2
and Supplementary Figs. 8, 9.
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what, if any, effect would be seen with the different AcrB
genotypes. PAβN incubation led to increased MIN and CIP
antibiotic susceptibility for both AcrBWT and AcrBG288D (Fig. 5d).
AcrBG288D being more susceptible to PAβN than AcrBWT. The
decreased susceptibility of AcrBG288D to CIP, found in Salmo-
nella30, was not recapitulated in our assays using the laboratory E.
coli strain MG1655. This may be due to CIP efflux via another
transporter found in E. coli but not in Salmonella. However, the
associated increased susceptibility to MIN was observed (Fig. 5d),
supporting that G288D has a profound impact on AcrB substrate
efflux within both E. coli and Salmonella.
Discussion
In summary, we found that binding of an EPI, PAβN, restricts
AcrB dynamics and could not be outcompeted by an antibiotic,
CIP, whose activity it potentiates. Fluorescence binding, MD
simulations, and docking studies supporting the existence of a
ternary protein–EPI–antibiotic complex. Endorsing the theory
that RND-pump inhibitors act through an “altered-dynamics”
mechanism, obstructing the translocation of substrates rather
than preventing their binding and recognition.
Furthermore, we reveal that an MDR-conferring AcrB drug-
pocket substitution, G288D30, modifies the structural dynamics of
the translocation pathway in a substrate-independent manner.
Our previous MD simulations30 show that the G288D substitu-
tion increases the gyration radius and hydration at and
around the DBP. This disruption could subsequently lead to the
observed allosteric action on farther AcrB regions. In turn, these
changes may alter the energetic barrier for substrate binding and
transport during functional rotation and, consequently, be the





























































ΔHDX = AcrBG288D – AcrBWT

















Fig. 4 Influence of MDR mutation G288D on AcrB structural dynamics. a In this zoom-in view of the DBP, within the L-state monomer of AcrB
(PDB:2HRT), the G288 position is shown as an orange sphere amongst the hydrophobic trap (purple) and alongside the switch loop (yellow). b Differential
HDX (ΔHDX) plots for AcrBG288D and AcrBWT with and without drugs. All data reported as in Fig. 2. 98% confidence intervals are shown as grey dotted
lines and grey data are peptides with insignificant ΔHDX. All measurements were performed at least in triplicate. All supporting HDX-MS peptide data can
be found in the Source Data file. (c) Shared regions surrounding the DBP whose HDX are increased (red) and decreased (blue) in a substrate-independent
manner (highlighted by the dashed boxes in Fig. 4b) are shown on both L- and T-state monomers of AcrB (PDB:2HRT). The connecting-loop from the
adjacent monomer is included. Substrate efflux pathways (magenta) for the periplasmic entrance are depicted using CAVER68.
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Here, to examine the structural dynamics of AcrB we per-
formed HDX-MS within DDM detergent micelles and supported
our findings with MD simulations completed within POPE/
POPG (2:1 ratio) lipid bilayers. Detergent and amphipol mem-
brane mimetics have been used extensively to obtain structural
information for the determination of drug binding interactions
and efflux mechanisms of AcrB. However, these systems do not
provide a lipid environment, which can modulate membrane
protein structure and function40. Recent studies have used SMA
lipid particle (SMALP) technology and liposome reconstitution to
capture AcrB within a lipid environment and solved its structure
at high-resolution using cryo-EM41–43. The resulting structures
were largely consistent with high-resolution crystal structures
solved in DDM detergent micelles, with homotrimeric AcrB
conformation remaining the same even when the surrounding
membranes display different curvatures43. This coupled with the
agreement found between our HDX-MS data and MD simula-
tions support that the structural dynamic behaviour uncovered
here informs on the native protein state, although further studies
investigating the effect of lipids on its dynamics are necessary to
understand the system in its entirety.
We anticipate that the findings reported here will be important
not only for establishing the general role of structural dynamics in
modulating AcrB multidrug binding and efflux, which are hard to
elucidate from biochemical and high-resolution structural data
alone, but also for defining how naturally occurring mutations
and EPI interactions affect its structure function.
Methods
Plasmid construction. An overexpression plasmid containing AcrB with a C-
terminal 6xHistidine tag (AcrB-6xHis) was constructed from a pET15b-AcrB-
sGFP-6xHis plasmid from Reading et al.44. Briefly, the sGFP sequence was deleted
and a 6xHis-tag placed at the C-terminus of AcrB followed by a stop codon using
the Q5® site-directed mutagenesis kit (New England Biolabs)—AcrB contains two
Histidine residues at its C-terminus, therefore, this construct resulted in AcrB
having an 8xHistidine tag. The G288D mutation was then generated from this
pET15b-AcrB-6xHis plasmid using the Q5® site-directed mutagenesis kit (New
England Biolabs). All constructs were verified by DNA sequencing (Eurofins
MWG). Primers used are reported in Supplementary Table 9.
pBR322-AcrB plasmids were generated for bacterial susceptibility assays.
Briefly, pBR322 was linearized with HindIII and EcoRI restriction enzymes (New
England Biolabs). acrAB genes with its natural promoter, including the “marbox”
sequence, was then amplified from K-12 Escherichia coli chromosomal DNA
(Zyagen Labs) and cloned into the pBR322 vector using In-Fusion® HD cloning
(Takara Bio). A 6xHistidine tag sequence was included in the reverse primer to
provide a 6xHis tag at the C-terminus of AcrB (pBR-AcrBWT). The G288D
mutation was generated from this pBR-AcrBWT plasmid using the Q5® site-
directed mutagenesis kit (New England Biolabs). All constructs were verified by
primer walking DNA sequencing (Eurofins MWG). Primers used are reported in
Supplementary Table 9.
AcrB overexpression and purification. pET15b-AcrB-6xHis plasmid containing
AcrB wildtype (AcrBWT) or G288D mutant (AcrBG288D) was transformed into C43
(DE3)ΔacrB::KanR E. coli cells. 7 ml of an overnight LB culture was added to 1 L of
pre-warmed LB culture containing 100 µg/ml ampicillin and 30 µg/ml kanamycin
and grown at 37 °C until an OD of 0.6–0.8 was reached. The culture was induced
with 1 mM IPTG and grown for 16–18 h at 18 °C. At which point the cells were
harvested by centrifugation at 4200 × g for 30 min and washed with ice-cold
phosphate buffer saline (PBS).
Cell pellets were immediately resuspended in buffer A (50 mM sodium
phosphate, pH 7.4, 300 mM sodium chloride) and supplemented with a protease
inhibitor tablet (Roche), 100 μM PMSF, 1 µl Benzonase, and 5 mM beta-
mercaptoethanol (β-ME). The cell suspension was then passed twice through a
microfluidizer processor (Microfluidics) at 25,000 psi and 4 °C. Insoluble material
was removed by centrifugation at 20,000 × g for 30 min at 4 °C. Membranes were
then pelleted from the supernatant by centrifugation at 200,000 × g for 1 h at 4 °C.
Membrane pellets were resuspended to 40 mgml−1 in ice-cold buffer A
supplemented with a protease inhibitor tablet (Roche) and 100 μM PMSF, and
homogenized using a Potter-Elvehjem Teflon pestle and glass tube.
AcrB was extracted from homogenized membranes by overnight incubation
with 1% (w/v) n-dodecyl-β-D-maltoside (DDM) detergent (Anatrace) at 4 °C with
gentle agitation. Insoluble material was then removed by centrifugation at 100,000
x g for 1 h at 4 °C. The sample was then filtered through a 0.22 μm filter (Fisher
Scientific) and loaded onto a 1 ml HiTrap column (GE Healthcare) equilibrated in
buffer B (50 mM sodium phosphate, pH 7.4, 300 mM sodium chloride, 20 mM
imidazole, 10% (w/v) glycerol, 0.03% (w/v) DDM). The column was washed with 5
CVs of buffer B and then with 10 CVs of buffer C (50 mM sodium phosphate, pH
7.4, 300 mM sodium chloride, 20 mM imidazole, 10 % (w/v) glycerol, 1% (w/v)
octyl glucose neopentyl glycol (OGNG) (Generon))—an OGNG detergent wash
facilitates the removal of bound lipopolysaccharide (LPS), as determined
previously45 (Supplementary Fig. 2c-e). The column was then washed with 20 CVs
of Buffer B containing 50 mM imidazole. AcrB was then eluted with Buffer B
containing 500 mM imidazole and directly injected onto a Superdex 75 10/600 GL
size exclusion chromatography (SEC) column (GE Healthcare) equilibrated in
buffer D (50 mM sodium phosphate, pH 7.4, 150 mM sodium chloride, 10% (w/v)
glycerol, 0.03% (w/v) DDM). A flow rate of 1 ml/min was used during HiTrap and
SEC purification. Peak fractions eluted from the SEC column containing pure AcrB
were pooled, spin concentrated using a 100 K MWCO concentrator (Amicon®),
and spin filtered before being flash frozen and stored at −80 °C. SDS-PAGE


































































Fig. 5 AcrBG288D is inhibited by the EPI PAβN. a Molecular docking and
multi-copy μs-long MD simulations reveal stable interactions of CIP
(orange) and PAβN (cyan) to AcrBG288D T-state monomer and show their
likely binding locations. The pose and its orientation are the same as shown
for AcrBWT in Fig. 3c. EG= exit channel gate (blue spheres), SL= switch-
loop (yellow), and HT= hydrophobic trap (purple). All computational data,
including binding free energies can be found in Supplementary Table 5 and
Supplementary Figs. 8, 14–16. b Binding of CIP by AcrBG288D in the
presence of 150 μM of PAβN as determined by a fluorescence polarization
assay performed by Su et al.39. All data are fit as in Fig. 3a (R2= 0.99).
Data are the average and standard deviation from independent
measurements (n= 3). c Binding competition assay between PAβN and CIP
for AcrBWT. Data are the average and standard deviation from independent
measurements (n= 3). d MIC assays of Escherichia coli containing AcrBWT
or AcrBG288D in the presence of PAβN and antibiotics. AcrB was
overexpressed in MG1655 ΔacrB from a pBR322 plasmid containing its
corresponding acrAB genes, natural promoter and “marbox” sequence.
Minocycline = MIN, ciprofloxacin = CIP, and phenylalanine-arginine-β-
naphthylamide = PAβN. †PAβN was added at a concentration of 50 μg/ml.
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calculated using a Cary 300 Bio UV–Vis spectrophotometer (Varian) with a
calculated extinction coefficient46 of ε280= 89,730M−1 cm−1.
Circular dichroism spectroscopy. Circular dichroism spectroscopy (CD) spectra
were recorded with an Aviv Circular Dichroism spectrophotometer, Model 410
(Biomedical Inc., Lakewood, NJ, USA), with specially adapted sample detection to
eliminate scattering artefacts. Multiple CD scans were averaged, the buffer back-
ground subtracted, and zeroed and minimally smoothed using CDTool47. A final
protein concentration of 0.5–1.5 mgml−1 was used in a quartz rectangular or
circular Suprasil demountable cell (Hellma Analytics). For thermal protein
unfolding the mean residue ellipticity at 222 nm was monitored with increasing
temperature.
Native mass spectrometry. Purified AcrB was buffer exchanged into MS buffer
(200 mM ammonium acetate, pH 7.4, 0.03% (w/v) DDM or Triton X-100) using a
centrifugal buffer exchange device (Micro Bio-Spin 6, Bio-Rad) according to the
manufacturer’s instructions48. Native mass spectrometry experiments were per-
formed either on a Synapt G2-Si mass spectrometer (Waters) or a Thermo Sci-
entific Q Exactive UHMR hybrid Quadrupole-orbitrap mass spectrometer.
For experiments on the Synapt G2-Si mass spectrometer the instrument settings
used were: 1.5 kV capillary voltage, source temperature of 25 °C, argon trap
collision gas, 180 V trap collision voltage, 120 V cone voltage, and 50 V source
offset. Data were processed and analyzed using MassLynx v.4.1 (Waters).
Native mass spectrometry data on a Thermo Scientific Q Exactive UHMR
hybrid Quadrupole-orbitrap mass spectrometer was acquired at resolving power
8750 at m/z 400 in the m/z range 2000–30.000. The instrument was optimized for
transmission and desolvation of integral membrane proteins. Critical parameters
throughout were relative pressure of 6, capillary temperature 250 °C, S-Lens RF
level 0, in-source trapping 200 and the HCD energy was 300%. Data were analyzed
by the use of Xcalibur software 4.3 and Biopharma Finder 3.1 (both Thermo Fisher
Scientific). Deconvoluted spectra were acquired using Biopharma Finder 3.1 in
sliding window mode using the following settings: Output mass range
10,000–100,000 Da, deconvolution mass tolerance 10 ppm, sliding window merge
tolerance 30 ppm and minimal number of detected intervals.
Preparation of ligands for hydrogen/deuterium mass spectrometry. Cipro-
floxacin (CIP) antibiotic and Phe-Arg-β-naphthylamide dihydrochloride (PAβN)
inhibitor were both purchased from Sigma Aldrich. Stock concentrations of CIP
(10 mg/ml) and PAβN (10 mg/ml) were prepared in 0.1 N HCl and water,
respectively. As demonstrated previously49, a primary consideration before carry-
ing out HDX-MS is to ensure close to full binding to the target protein under
deuterium exchange conditions; particularly for low-affinity ligands (dissociation
constants, kD, in the μM range or lower). CIP and PAβN both possess moderate
affinity binding to AcrB within DDM detergent micelles (CIP with a kD of 74.1 ±
2.6 μM, as measured by fluorescence polarization39 and PAβN with a kD of 15.72 ±
3.0 μM, as measured by surface plasmon resonance50). To achieve sufficient ligand
binding saturation under deuterium exchange conditions AcrB was first incubated
in the presence of saturating concentrations of ligand for 30 minutes on ice, before
dilution into deuterated buffer containing saturating concentrations of ligand (740
μM, ∼1000:1 ligand to AcrB ratio) for deuterium exchange experiments.
Hydrogen/deuterium mass spectrometry. Hydrogen/deuterium mass spectro-
metry (HDX-MS) was performed on an HDX nanoAcquity ultra-performance
liquid chromatography (UPLC) Synapt G2-Si mass spectrometer system (Waters
Corporation). Optimized peptide identification and peptide coverage for AcrB was
performed from undeuterated controls. The optimal sample workflow for HDX-
MS of AcrB was as follows: 5 μl of AcrB (15 μM) was diluted into 95 μl of either
buffer D or deuterated buffer D at 20 °C. After fixed times of deuterium incubation
samples were mixed with 100 μl of formic acid-DDM quench solution to provide a
quenched sample at pH 2.5 and final 0.075% (w/v) DDM concentration. 80 μl of
the quenched sample was then loaded onto a 50 μl sample loop before being
injected onto an online Enzymate™ pepsin digestion column (Waters) in 0.1 %
formic acid in water (at a flow rate of 200 μl/min) maintained at 20 °C. The peptic
fragments were trapped onto an Acquity BEH C18 1.7 μM VANGUARD pre-
column (Waters) for 3 min. The peptic fragments were then eluted using an 8–40%
gradient of 0.1% formic acid in acetonitrile at 40 μl/min into a chilled Acquity
UPLC BEH C18 1.7 μM 1.0 ×100 mm column (Waters). The trap and UPLC
columns were both maintained at 0 °C. The eluted peptides were ionized by
electrospray into the Synapt G2-Si mass spectrometer. MSE data was acquired with
a 20–30 V trap collision energy ramp for high-energy acquisition of product ions.
Argon was used as the trap collision gas at a flow rate of 2 mL/min. Leucine
enkephalin was used for lock mass accuracy correction and the mass spectrometer
was calibrated with sodium iodide. The online Enzymate™ pepsin column was
washed three times with pepsin wash (1.5 M Gu-HCl, 4 % MeOH, 0.8% formic
acid), as recommended by the manufacturer, and a blank run was performed
between each sample to prevent significant peptide carry-over between runs.
All deuterium time points and controls were performed in triplicate. Sequence
identification was performed from MSE data of digested undeuterated samples of
AcrB using the ProteinLynx Global Server 2.5.1 software. The output peptides were
then filtered using DynamX (v. 3.0) using the following filtering parameters:
minimum intensity of 1000, minimum and maximum peptide sequence length of 4
and 25, respectively, minimum MS/MS products of 1, minimum products per
amino acid of 0.12, and a maximum MH+ error threshold of 15 ppm. Additionally,
all the spectra were visually examined and only those with a suitable signal to noise
ratios were used for analysis. The amount of relative deuterium uptake for each
peptide was determined using DynamX (v. 3.0) and was not corrected for back
exchange32. The relative fractional uptake (RFU) was calculated from RFUa= [Ya,t/
(MaxUptakea × D)], where Y is the deuterium uptake for peptide a at incubation
time t, and D is the percentage of deuterium in the final labelling solution.
Confidence intervals for differential HDX-MS (ΔHDX) measurements of any
individual time point were then determined according to Houde et al.51 using
Deuteros software (v. 1.0)34. There was no correlation found between ΔHDX values
and their standard deviations (R2= 0.09). Only peptides which satisfied a ΔHDX
confidence interval of 98% were considered significant. All ΔHDX AcrB structure
figures were generated from the data using Deuteros in-house source code/
software34 and Pymol52. All supporting data and meta-data are reported in the
Source data file and Supplementary Data 1-4.
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identifier PXD019047 [http://www.ebi.ac.uk/pride/archive/projects/PXD019047].
Bacterial susceptibility assays. Antimicrobial susceptibility testing of all wildtype
and mutant strains in the absence or presence of PAβN was determined in tri-
plicate by the broth microdilution (BMD) method and the standardized agar
doubling-dilution method as recommended by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST). EUCAST guidelines were followed
conforming to ISO 20776-1:200653,54. Antibiotics and EPIs were made up and used
according to the manufacturer’s instructions. E. coli ATCC 25922 was used as the
control strain.
Fluorescence polarization. AcrB ligand binding was determined using fluores-
cence polarization (FP) assays as performed by Su et al.39. An AcrB–PAβN protein
complex stock was prepared; to ensure a loaded complex, AcrB and 150 μM PAβN
was incubated for 2 h at 25 °C before titrating with 1.5 μM CIP (kD of PAβN is
15.72 ± 3.0 μM, as measured by surface plasmon resonance50). AcrB protein
titration experiments were performed in ligand binding solution (50 mM sodium
phosphate, 150 mM sodium chloride, 10% (v/v) glycerol, 1.5 μM CIP, 150 μM
PAβN, 0.03% (w/v) DDM, pH 7.4). FP measurements were taken after incubation
for 5 min for each corresponding protein concentration to ensure that the binding
has reached equilibrium. Ligand binding data was fit to a hyperbola function (FP=
(Bmax*[protein])/(kD+ [protein])) as performed previously by Su et al.39 using
ORIGIN Ver. 7.5. (OriginLab Corporation, Northampton, MA, USA).
A FP competition assay was performed by titrating increasing concentrations of
PAβN (0–1000 µM) to a AcrB–CIP preformed complex concentration adjudged
from the binding data (1.5 µM CIP and 45 µM AcrB)—CIP and AcrB were
maintained at the same concentration during all PAβN titrations. FP
measurements were taken after incubation for 5 min for each corresponding
protein concentration to ensure that the binding has reached equilibrium.
Each data point was an average of 15 FP measurements and each titrations
series was performed three times. The absorption spectra of PAβN from 350 to 500
nm exhibited that PAβN absorbs light at 350 and 370 nm. The excitation
wavelength of CIP at 415 nm does not excite PAβN, therefore PAβN can be
considered as a non-fluorescent ligand within these experiments. DDM detergent
concentration was consistent to eliminate possible changes in polarization by
drug–DDM micelle interactions.
Molecular docking. A blind docking campaign was first performed using Auto-
dock Vina55. As done in Atzori et al.56, a rectangular search space of size 125 Å ×
125 Å × 110 Å enclosing the whole portion of the protein potentially exposed to
ligands was adopted. The exhaustiveness parameter, related to the extent of the
exploration within the search space, was set to 8192 (~1000 times the default 8) in
order to improve the sampling of docking poses within the large box used (~64
times the default 30 Å × 30 Å × 30 Å). Flexibility of both partners was considered
indirectly, by employing multiple conformations in ensemble docking runs57. For
both CIP and PAβN, 10 representative molecular conformations were obtained
from 1 μs long molecular dynamics simulations of the compounds in the presence
of explicit solvent58 (data available at www.dsf.unica.it/translocation/db). Namely,
a cluster analysis of the trajectories of the ligands was performed as described in
Malloci et al.58, setting the number of cluster representatives to 10.
For the wildtype receptor (AcrBWT), 10 X-ray asymmetric high-resolution
structures (with PDB IDs: 2GIF, 2DHH, 2J8S, 3W9I, 4DX5, 4DX7, 4U8V, 4U8Y,
4U95, 4U96) were considered, most bearing a substrate bound to the transporter.
For the G288D variant of AcrB (AcrBG288D), we also employed 10 structures,
namely the homology models derived on top of the AcrBWT X-ray structures
mentioned above. Regarding the homology modelling protocol, the sequence of the
G288D variant was first generated by manually modifying the FASTA file of the
corresponding amino acid sequence of E. coli AcrB retrieved from the Uniprot
database (Uniprot Id: P31224). Next, 100 homology models were generated for
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each template with the Modeller 9.2159 software. The variable target function
method was used to perform the optimization, and the best model (that is the one
with the highest value of the MOLPDF function) was employed in docking
calculations.
The ensemble docking campaign resulted in several hundred poses per ligand,
most of which were located inside the DBP of the monomer in the T-state (DBPT),
which is the putative binding site for the recognition of low molecular mass
compounds such as those studied here11 (see Supplementary Table 1). Because
most docking poses were concentrated in this region, we performed a second
docking campaign using a grid of 30 Å × 30 Å × 30 Å and centred at DBPT. Next,
we performed a cluster analysis of the docking poses using as a metric the heavy
atoms Root Mean Square Deviation (RMSD) of the substrate (setting the cut-off to
3 Å), which returned respectively 11, 9, 15, and 17 different poses for the
AcrBWT–PAβN, AcrBWT–CIP–PAβN, AcrBG288D–PAβN, AcrBG288D–CIP–PAβN
complexes (Supplementary Tables 2, 5). Moreover, to evaluate how the presence of
PAβN affects the binding of CIP in the ternary complexes, we selected three
docking poses of CIP onto AcrBWT and AcrBG288D. In the case of the AcrBWT–CIP
complex, to consider the largest number of putative binding modes, we purposely
selected docking poses with an orientation different than that reported previously29
(Supplementary Fig. 16).
Molecular dynamics simulations. All of the 52 complexes selected from docking
runs were subjected to all-atom molecular dynamics (MD) simulations (each of 1
μs in length) performed with the AMBER18 package60.
Protomer-specific protonation states of AcrB were adopted following previous
work61: residues E346 and D924 were protonated only in the L and T protomers,
while residues D407, D408, and D566 were protonated only in the O protomer, of
AcrB. The topology and the initial coordinate files were created using the LEaP
module of the AMBER18 package. The proteins were embedded in a mixed bilayer
patch composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE)
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) in a 2/1 ratio, for a
total of 660 lipid molecules symmetrically distributed in the two leaflets of the bilayer.
The whole system was solvated with a 0.15M aqueous NaCl solution. The AMBER
force-field protein.fb1562 was used to represent the protein; lipid17 (http://ambermd.
org/GetAmber.php) parameters were used for the POPE molecules; the TIP3PFB
model was employed for water63. The General Amber Force-Field (GAFF)
parameters64 for CIP and PAβN were taken from Malloci et al58.
Each system was first subjected to a multi-step structural relaxation via a
combination of steepest descent and conjugate gradient methods using the pmemd
program implemented in AMBER18, as described in previous publications4,29,61. The
systems were then heated from 0 to 310 K in two subsequent MD simulations: (i)
from 0 to 100 K in 1 ns under constant-volume conditions and with harmonic
restraints (k= 1 kcal mol−1·Å−2) on the heavy atoms of both the protein and the
lipids; (ii) from 100 to 310 K in 5 ns under constant pressure (set to a value of 1 atm)
and with restraints on the heavy atoms of the protein and on the z coordinates of the
phosphorous atoms of the lipids to allow membrane rearrangement during heating.
As a final equilibration step, a series of 20 equilibration steps, each of which was 500
ps in duration (total 10 ns), with restraints on the protein coordinates, were
performed to equilibrate the box dimensions. These equilibration steps were carried
out under isotropic pressure scaling using the Berendsen barostat, whereas a Langevin
thermostat (collision frequency of 1 ps−1) was used to maintain a constant
temperature. Finally, production MD simulations of 1 μs were performed under an
isothermal-isobaric ensemble for each system. A time step of 2 fs was used for all runs
before production, while the latter runs were carried out with a time step of 4 fs after
hydrogen mass repartitioning65.
During the MD simulations, the lengths of all the R–H bonds were constrained
with the SHAKE algorithm. Coordinates were saved every 100 ps. The Particle
mesh Ewald algorithm was used to evaluate long-range electrostatic forces with a
non-bonded cut-off of 9 Å.
Post-processing of MD trajectories. MD trajectories were analyzed using either
in-house tcl and bash scripts or the cpptraj tool of AMBER18. Figures were pre-
pared using gnuplot 5.066 and VMD 1.9.367. All the calculations with the exception
of the cluster analysis were performed on the conformations taken from the most
populated conformational cluster (representing the most sampled conformation of
the complex along the production trajectories) along the last 300 ns of the
production runs.
Cluster analysis. Clustering of the ligand trajectory was carried out using the
average-linkage hierarchical agglomerative clustering method implemented in
cpptraj and employing an RMSD cut-off of 3 Å calculated on all the heavy atoms of
the ligand.
System stability. The RMSDs of the protein and of the substrates were calculated
using cpptraj after structural alignment of each trajectory (reported in
Supplementary Table 10). Namely, we calculated the Cα-RMSD of the protein with
respect to the initial (docking) structure after alignment of the whole trimer. The
RMSDs of the substrates were calculated with respect to the corresponding
structure of the selected docking pose, as well as with respect to the last frame of
the MD trajectory. In particular. To evaluate the magnitude of the displacements
and reorientations of the substrates during the simulations, their RMSDs were
calculated upon alignment of the T monomer of the protein to the reference frame.
Interaction network. Interactions stabilizing the complexes were analyzed by
considering residues within 3.5 Å of each substrate in the last 300 ns of the MD
trajectories. Hydrogen bonds were identified through geometrical criteria, using a
cut-off of 3.2 Å for the distance between donor and acceptor atoms and a cut-off of
135° for the donor-hydrogen-acceptor angle. Such analyses were conducted
through in-house tcl scripts. Occupancy levels of hydrogen bonds and water-
mediated interactions (detected in the last 300 ns of each simulation) were also
computed using cpptraj. For systems AcrBWT–PAβN, AcrBWT–CIP-PAβN,
AcrBG288D–PAβN and AcrBG288D–CIP-PAβN, the following analyses were also
performed to evaluate their agreement with HDX-MS data.
System flexibility. The Root Mean Square Fluctuations (RMSFs) of the protein
were calculated using cpptraj after structural alignment of each trajectory as
described in the previous paragraph.
Hydration properties. Residue-wise average numbers of waters within the first
(second) hydration layer were calculated with cpptraj using a distance cut-off of 3.4
(5.0) Å between the nitrogen of the protein and the water oxygens.
Comparison with HDX-MS data. RMSFs and hydration properties of each
system were compared with a proper reference state according to the current
knowledge about the most likely conformations assumed by AcrB in the absence
of ligands or complexed with substrates and inhibitors16. For instance, to
account for conformational changes of AcrB induced by inhibitor binding,
PAβN-bound and apo AcrB structures were considered in their T- and L-state,
respectively. The T-state was also considered for systems containing both
PAβN and CIP (AcrBWT–CIP–PAβN and AcrBG288D–CIP–PAβN),
hypothesizing their stability in this conformation, as evidenced by the RMSDs
analyses conducted on our trajectories (Supplementary Figs. 6, 9, 12, 14). The
list of reference states used for each analysis are reported in Supplementary
Table 11.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this manuscript are available from the corresponding
authors upon reasonable request. The molecular dynamics trajectories will be available
anyone at any time by sending an e-mail to Attilio Vittorio Vargiu (vargiu@dsf.unica.it).
A reporting summary for this Article is available as a Supplementary Information file.
Mass spectrometry data files including processed DynamX files have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identifier PXD019047. HDX-MS meta-data have been provided in Supplementary Data
files 1–4 with this paper. Source data are provided with this paper.
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